Cancer Discovery·· 2026-09-01评分54
Disitamab vedotin联合tislelizumab和S-1一线治疗HER2过表达胃癌显示疗效
First-Line HER2 ADC and Anti–PD-1 Plus Chemo Shows Efficacy in Gastric Cancer
导读
Disitamab vedotin联合tislelizumab和S-1一线治疗HER2过表达胃及胃食管结合部腺癌的II期试验达到89.5%的确认客观缓解率。该HER2靶向抗体药物偶联物联合抗PD-1和口服化疗方案显示出安全性和疗效证据，值得进一步临床评估。
来源：Cancer Discovery · aacrjournals.org